Clinical Trials on NSCLC (Non-small Cell Lung Cancer)

Total 8034 results

Hoffmann-La Roche

Completed

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy (OAK)

Non-Squamous Non-Small Cell Lung Cancer

United States, Italy, Canada, Austria, Finland, France, Greece, Korea, Republic of, Panama, Portugal, Spain, Turkey, United Kingdom, Taiwan, Brazil, Germany, Poland, Chile, Guatemala, Russian Federation, Switzerland, Thailand, Ukraine, Serb... and more
Hoffmann-La Roche

Completed

A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Non-Squamous Non-Small Cell Lung Cancer

Portugal
Lingyu Luo

Unknown

Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin

Non-squamous Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer

Non-squamous Non-small Cell Lung Cancer

China
Fujian Cancer Hospital

Unknown

Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel

Non-squamous Non-small Cell Lung Cancer
Jian Fang
Peking University First Hospital; Peking University Third Hospital; The Second...

Unknown

Apatinib in Advanced Non-squamous，NSCLC

Non-squamous Non-Small Cell Lung Cancer

China
Hoffmann-La Roche

Completed

An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT)

Non-Squamous Non-Small Cell Lung Cancer

Spain
Hoffmann-La Roche

Completed

An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)

Non-Squamous Non-Small Cell Lung Cancer

Germany
Hoffmann-La Roche

Completed

An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

Germany
Hoffmann-La Roche

Completed

An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

France
Hoffmann-La Roche

Completed

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Non-Squamous Non-Small Cell Lung Cancer

Spain, Taiwan, Japan, United States, France, Germany, Korea, Republic of, Malaysia
Hoffmann-La Roche

Terminated

A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment (STAR)

Non-Squamous Non-Small Cell Lung Cancer

Romania
Genentech, Inc.

Completed

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

Spain, France, United States, United Kingdom, Latvia, Italy, Israel, Argentina, Germany
Abramson Cancer Center of the University of Pennsylvania

Active, not recruiting

The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy

Non-small Cell Lung Cancer

United States
Philogen S.p.A.

Completed

Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients

Breast Cancer | Solid Tumor | Metastatic Melanoma | Non-small Cell Lung Cancer (NSCLC)

Italy
Hunan Province Tumor Hospital

Recruiting

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC (PROFILE)

Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | RET Gene Mutation | MET Amplification

China
Institut Cancerologie de l'Ouest

Recruiting

Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy (TRAILOCLORI01)

Metastatic Non Small Cell Lung Cancer | Locally Advanced Non Small Cell Lung Cancer

France
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Recruiting

Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Daiichi Sankyo
AstraZeneca

Available

Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients

Advanced Non-Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer

United States, Austria, Spain
AstraZeneca

Completed

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

Belgium, United States, Korea, Republic of, Taiwan, United Kingdom, Netherlands
AstraZeneca

Completed

AZD9291 First Time In Patients Ascending Dose Study (AURA)

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

United States, France, Germany, Korea, Republic of, Taiwan, United Kingdom, Spain, Italy, Japan, Australia
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC

Active, not recruiting

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Metastatic Non Small Cell Lung Cancer | Recurrent Non Small Cell Lung Cancer

United States
Intergroupe Francophone de Cancerologie Thoracique
ANRS, Emerging Infectious Diseases

Completed

Immunotherapy by Nivolumab for HIV+ Patients (CHIVA2)

HIV/AIDS | Non Small Cell Lung Cancer Stage IIIB | Non Small Cell Lung Cancer Metastatic

France
OHSU Knight Cancer Institute
AstraZeneca; Oregon Health and Science University

Completed

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
Chonnam National University Hospital
Roche Pharma AG

Completed

A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response (MENTOR)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Recurrent

Korea, Republic of
National Cancer Institute (NCI)

Completed

Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Withdrawn

CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Fox Chase Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Recurrent

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Withdrawn

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)

Completed

Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer

Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Extensive Stage Small Cell Lung Carcinoma | Squamous Cell Lung Carcinoma | Recurrent Small Cell Lung Carcinoma

United States
Beth Israel Medical Center
St. Luke's-Roosevelt Hospital Center

Terminated

Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (METRO)

Nonsquamous Nonsmall Cell Neoplasm of Lung | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB/IV

United States
NovaRx Corporation

Completed

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP)

Lung Neoplasm | Carcinoma Non-small Cell Lung Cancer Stage IIIA | Carcinoma Non-small Cell Lung Cancer Stage IIIB | Carcinoma Non-small Cell Lung Cancer Stage IV

United States, Hungary, United Kingdom, Netherlands, Canada, India, Poland, Serbia
National Cancer Institute (NCI)

Active, not recruiting

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States, Puerto Rico
National Cancer Center Hospital East
AstraZeneca; Japan Agency for Medical Research and Development; Japan Clinical...

Not yet recruiting

Efficacy and Safety of CRT, Durvalumab and Surgery for SST (DEEP_OCEAN)

Non Small Cell Lung Cancer Stage III | Superior Sulcus Tumor | Non-small Cell Lung Cancer Stage IIB
Daiichi Sankyo
Daiichi Sankyo Co., Ltd.

Active, not recruiting

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

United States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
Hellenic Cooperative Oncology Group

Completed

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Gene Mutation
Cancer Institute and Hospital, Chinese Academy...

Unknown

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Non Small Cell Lung Cancer | Stage III Non-small-cell Lung Cancer | EGFR Mutation-Related Tumors
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.

Recruiting

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Advanced Solid Tumor | Non-small Cell Lung Cancers

United States
Chongqing University Cancer Hospital

Recruiting

Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

Non-Small Cell Lung Cancer (NSCLC)

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer

Recurrent Lung Non-Small Cell Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States, Canada
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Megan Daly, MD
National Cancer Institute (NCI); Genentech, Inc.

Terminated

MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
University of Washington
National Cancer Institute (NCI); Celgene Corporation

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Biocad

Unknown

Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS) (DOMINUS)

Non Small Cell Lung Cancer Stage IIIB | Non-Small Cell Carcinoma of Lung, TNM Stage 4

Russian Federation, Belarus
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer (ARC-4)

Non Small Cell Lung Cancer | Nonsquamous Nonsmall Cell Neoplasm of Lung | Non Small Cell Lung Cancer Metastatic | Sensitizing EGFR Gene Mutation

United States, Korea, Republic of, Singapore, Taiwan
NeoImmuneTech
Roche Pharma AG

Active, not recruiting

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Non-Small Cell Lung Carcinoma

United States
Hoffmann-La Roche

Completed

Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China

Non-Small Cell Lung Cancer, Lung Cancer, Cancer

China

Clinical Trials on NSCLC (Non-small Cell Lung Cancer)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations